Sleep Apnea (Obstructive and Central)
Sleep apnea isn't one uniform problem — it's a group of sleep-breathing disorders with distinct mechanisms: obstructive (OSA), caused by mechanical collapse of the throat, and central (CSA), caused by instability of the brain's breathing control — united by a shared outcome: repeated overnight drops in blood oxygen and fragmented sleep.
Number of studies
2
Safety
Requires caution
Time to effects
Improved sleep quality and daytime alertness with properly fitted CPAP therapy can be noticeable after just the first few nights, but a measurable reduction in cardiovascular and metabolic risk requires consistent, long-term use of therapy over months and years.
Who it's for
Table of contents
TL;DR
Sleep apnea isn't one uniform problem — it's a group of sleep-breathing disorders with distinct mechanisms: obstructive (OSA), caused by mechanical collapse of the throat, and central (CSA), caused by instability of the brain's breathing control — united by a shared outcome: repeated overnight drops in blood oxygen and fragmented sleep.
- →Correctly distinguishing OSA from CSA determines entirely different, targeted treatment — confusing the two leads to ineffective therapy
- →Treating moderate-to-severe OSA (e.g., with CPAP) is associated in studies with reduced blood pressure and better control of cardiovascular disease
- →Effective therapy improves daytime alertness and reduces the risk of drowsiness-related traffic accidents
| Disorder type | Obstructive (OSA), central (CSA), or mixed sleep apnea — repeated episodes of apnea/hypopnea during sleep |
|---|---|
| Prevalence | OSA of any severity affects an estimated nearly a billion adults worldwide; CSA is far rarer and usually secondary to another condition |
| Risk group | Obesity, male sex, middle/older age, craniofacial abnormalities (OSA); heart failure, prior stroke, opioid use, high altitude (CSA) |
| Key symptoms | Loud, irregular snoring, witnessed breathing pauses, excessive daytime sleepiness, morning headaches — women often present with insomnia and fatigue rather than sleepiness |
| Diagnosis | Polysomnography (gold standard) or home sleep apnea testing (HSAT) in patients with a high pretest probability of uncomplicated OSA |
| Treatment | CPAP, oral appliances, positional therapy, and weight loss (OSA); treating the underlying disease and, in select cases, adaptive servo-ventilation (CSA) |
Understand
Overview
Sleep apnea is an umbrella term for sleep-breathing disorders involving repeated episodes of complete airflow cessation (apnea) or substantial reduction (hypopnea), typically lasting at least 10 seconds and recurring many times each hour of sleep. Clinically, the same symptom arises from two fundamentally different mechanisms: obstructive sleep apnea (OSA), where the airway physically collapses despite ongoing respiratory effort, and central sleep apnea (CSA), where the airway stays open but the brain temporarily stops sending the signal to breathe. A mixed form combining features of both also exists. This distinction isn't an academic nuance — it determines entirely different diagnostic workups and treatments, and confusing one for the other leads to ineffective therapy.
The clinical significance of sleep apnea goes beyond sleep quality alone, though fragmented sleep architecture and chronic sleep loss carry serious consequences on their own. Each episode ends in a micro-arousal and a sharp surge in sympathetic nervous system activity, and the accompanying periodic drops in blood oxygen (intermittent hypoxia) trigger a cascade of inflammatory and oxidative processes that burden the cardiovascular system. That's why untreated moderate-to-severe sleep apnea is associated in population studies with elevated risk of hypertension, atrial fibrillation, stroke, heart failure, and insulin resistance — it isn't merely a "snoring problem," but a cardiometabolic risk factor with measurable consequences.
The scale of the problem is far larger than commonly assumed. According to a 2019 literature-based analysis by Benjafield and colleagues, drawing on data from more than a dozen countries extrapolated to the global population, nearly a billion adults aged 30-69 worldwide have obstructive sleep apnea of some severity, with a substantial share having a moderate-to-severe form requiring treatment. Central sleep apnea is far rarer and, in the vast majority of cases, secondary to another condition — most often heart failure, a history of stroke, chronic opioid use, or high altitude. Key OSA risk factors include overweight and obesity (especially visceral and peripharyngeal fat), male sex, middle and older age, craniofacial abnormalities (a recessed jaw, a narrow airway), enlarged tonsils, smoking, and a family history of the condition.
The clinical picture can be misleading, leading to significant underdiagnosis in certain groups. The textbook image — a loudly snoring, overweight man whose partner notices breathing pauses — describes only part of the patient population. Women with OSA more often report atypical symptoms: insomnia, fatigue, low mood, or morning headaches, rather than obvious daytime sleepiness, which frequently leads to misdiagnosis as depression or primary insomnia instead of sleep apnea. Central sleep apnea can be even harder to recognize clinically, since snoring may be minimal or absent, and the dominant symptom is often nighttime breathlessness or an unsettling, irregular breathing pattern — typically Cheyne-Stokes breathing in patients with heart failure. There's also a genuine gray zone of severity — a patient with a borderline-mild apnea index but pronounced daytime symptoms may benefit more from treatment than a patient with a formally moderate index but no symptoms, which shows why the raw number of events per hour should never be the sole basis for a treatment decision.
A common misconception equates sleep apnea with snoring alone — snoring is a very common but nonspecific symptom, occurring in many people without any apnea episodes, while a portion of patients with significant CSA don't snore at all. Another misunderstanding is treating CPAP as the sole, universal treatment for every case of sleep apnea — in reality, the choice of therapy depends on the type and severity of the disorder and its underlying cause, and CSA treatment focuses primarily on the underlying disease, not the breathing symptom itself.
Diagnostically, polysomnography (PSG) performed in a sleep laboratory remains the gold standard, simultaneously recording airflow, chest and abdominal respiratory effort, blood oxygen saturation, brain activity (EEG), and other parameters — it's specifically the recording of respiratory effort that distinguishes an obstructive episode (effort present, airway blocked) from a central one (no effort, no signal from the brain). In adults with a high clinical probability of uncomplicated OSA and no significant comorbidities, home sleep apnea testing (HSAT) is a fully accepted, simpler alternative, recommended by American Academy of Sleep Medicine guidelines.
Obstructive and central sleep apnea, despite sharing a name and a partly overlapping clinical picture, are two different disorders requiring different diagnostic and therapeutic approaches. Understanding this distinction — mechanical obstruction on one hand, instability of the brain's breathing control on the other — is the starting point for proper diagnosis, and effective treatment almost always requires combining an intervention targeting the breathing symptom itself with addressing its underlying drivers, from body weight to cardiovascular disease.
Mechanism of action
In obstructive sleep apnea, the key driver is loss of tone in the pharyngeal dilator muscles (including the genioglossus) during sleep, most pronounced during REM sleep, when physiological muscle atonia is deepest. In anatomically predisposed individuals — those with excess fat around the throat, a recessed jaw, enlarged tonsils, or a narrow airway — the drop in muscle tone combined with the negative pressure generated during inhalation causes the airway to partially or completely collapse. This is quantified by the concept of critical closing pressure (Pcrit): the higher (less negative) the Pcrit, the more readily the throat collapses; in healthy people without OSA, Pcrit is clearly negative, while in severe OSA it can approach positive values, indicating a tendency for the airway to close even under normal pressure.
Alongside anatomical factors, a phenomenon known as high "loop gain" also plays a role — an oversensitive, unstable breathing-control feedback loop in which even small fluctuations in blood CO2 trigger a disproportionately strong response from the respiratory center, producing alternating episodes of hyperventilation and apnea. High loop gain worsens severity in a subset of OSA patients and is also the key mechanism in central sleep apnea, where instability of breathing control, rather than a mechanical obstruction, is the primary cause.
Central sleep apnea has a different pathophysiological basis depending on the clinical context. In its most common form, secondary to heart failure, Cheyne-Stokes breathing occurs — a cyclical waxing and waning of breath amplitude interrupted by apneas, resulting from a prolonged circulation time between the lungs and the brain's chemoreceptors, which causes the respiratory center to react to CO2 levels from several dozen seconds earlier rather than the current level, systematically "overcorrecting" its response. Other CSA mechanisms include respiratory center depression by opioids (acting directly on brainstem opioid receptors that regulate breathing rhythm), unstable breathing control after a stroke affecting brainstem centers, and periodic breathing that occurs physiologically at high altitude due to hypoxic hyperventilation.
Regardless of the primary cause, repeated apnea episodes set off a shared cascade of consequences: each episode ends in a micro-arousal that restores muscle tone and airway patency, accompanied by a sharp spike in sympathetic activity and a momentary rise in blood pressure. Repeated hundreds of times over a single night, this sequence of intermittent hypoxia and micro-arousals drives chronic sympathetic activation that persists into the daytime, oxidative stress, vascular endothelial dysfunction, and low-grade inflammation — these mechanisms, not sleepiness alone, explain the long-term cardiovascular and metabolic risk associated with untreated sleep apnea.
Loss of throat muscle tone during sleep
Reduced activity of the pharyngeal dilator muscles, most pronounced during REM sleep, favors airway collapse in anatomically predisposed individuals.
Critical closing pressure (Pcrit)
The less negative the Pcrit, the more readily the throat mechanically collapses during normal inhalation — a key parameter determining susceptibility to OSA.
Respiratory control instability and high loop gain
An oversensitive breathing-control loop responds disproportionately to CO2 fluctuations, producing the alternating hyper- and hypoventilation typical of CSA, especially Cheyne-Stokes breathing in heart failure.
The cascade of intermittent hypoxia and micro-arousals
Apnea and micro-arousal episodes repeated hundreds of times a night activate the sympathetic nervous system and trigger oxidative stress and endothelial dysfunction, underlying cardiovascular risk.
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythSleep apnea only affects loudly snoring, overweight men.
FactWomen, lean individuals, and patients with central sleep apnea often present atypically — without obvious snoring, with predominant insomnia, fatigue, or morning headaches rather than clear daytime sleepiness, leading to frequent underdiagnosis in these groups.
MythIf I snore, I definitely have sleep apnea.
FactSnoring is a very common but nonspecific symptom, occurring in many people with no apnea episodes at all — snoring alone isn't enough for a diagnosis, which requires confirmation with a sleep study (PSG or HSAT).
MythUntreated sleep apnea is just a daytime fatigue problem.
FactRepeated hypoxia and micro-arousal episodes drive mechanisms underlying elevated risk of hypertension, atrial fibrillation, stroke, and insulin resistance — the consequences reach far beyond sleepiness alone.
MythCPAP is the only effective treatment for every case of sleep apnea.
FactThe choice of therapy depends on the type and severity of the disorder — mild and moderate OSA can respond to weight loss, positional therapy, or oral appliances, while central sleep apnea primarily requires treating the underlying disease rather than CPAP alone.
Forms & variants
Sleep Apnea (Obstructive and Central) comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Obstructive sleep apnea (OSA)
The most common form — mechanical collapse of the throat despite ongoing respiratory effort, usually against a background of anatomical predisposition and excess fat around the throat.
Best for: Typically associated with obesity and loud snoring, though it also occurs in lean individuals and women with an atypical symptom picture
Central sleep apnea (CSA)
A rarer form — no breathing signal from the brain despite an open airway, most often secondary to heart failure, stroke, opioid use, or high altitude.
Best for: Primarily requires treating the underlying disease, not just an intervention targeting breathing itself
Complex/mixed apnea (including treatment-emergent)
Combines obstructive and central features; a central component sometimes emerges or worsens only after starting CPAP therapy for OSA.
Best for: May require modified therapy, such as switching to bilevel ventilation, under a sleep medicine specialist's supervision
Personalized for you
Struggling with sleep?
Answer a few questions about your sleep, stress, diet, and lifestyle. VitMode will show you which areas might need the most attention and which supplements could be worth considering.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
In obstructive sleep apnea (OSA), the airway physically collapses despite ongoing chest and abdominal respiratory effort. In central sleep apnea (CSA), the airway stays open, but the brain temporarily stops sending the signal to breathe, so respiratory effort disappears too. This distinction requires recording respiratory effort during a sleep study and determines an entirely different treatment approach.
No. Snoring is a common but nonspecific symptom of OSA, and some patients — especially those with central sleep apnea or an atypical clinical picture (more often women) — can have significant sleep apnea with minimal or no snoring at all.
In many cases of moderate and severe OSA, yes, because the therapy addresses the symptom without permanently removing the anatomical cause. However, with substantial weight loss, effective positional therapy, or surgical treatment, severity can decrease enough that the need for CPAP is reduced or resolved — any change in therapy is always decided by a physician based on a follow-up sleep study.
A prolonged circulation time between the lungs and the brain's chemoreceptors in heart failure patients causes the respiratory center to react to delayed information about CO2 levels, producing the cyclical waxing and waning of breathing known as Cheyne-Stokes breathing — one of the most common forms of central sleep apnea.
In adults with a high clinical probability of uncomplicated obstructive sleep apnea and no significant comorbidities, home sleep apnea testing (HSAT) is an accepted alternative under American Academy of Sleep Medicine guidelines. When central sleep apnea, other sleep disorders, or significant comorbidities are suspected, full in-lab polysomnography remains the preferred test.
What actually helps
CPAP (continuous positive airway pressure)
Strong evidenceFirst-line treatment for moderate and severe OSA — pneumatically "splints" the airway open, preventing collapse.
Oral appliances (mandibular advancement devices)
Moderate evidenceAdvance the lower jaw forward, widening the throat space — an alternative for mild/moderate OSA or CPAP intolerance.
Weight loss
Moderate evidenceReducing fat tissue around the throat lowers OSA severity, and substantial weight loss can lead to remission of mild forms.
Positional therapy
Moderate evidenceIn patients whose episodes worsen mainly in the supine position, avoiding sleeping on the back reduces the apnea index.
Treating the underlying disease in CSA
Moderate evidenceOptimizing heart failure treatment, reducing opioid doses, or post-stroke care addresses the primary cause of central apnea rather than just the symptom.
What to combine with
Good combinations
Sleep — Understanding normal sleep architecture and physiology makes it easier to understand why sleep fragmentation in sleep apnea has such broad health consequences
Obesity — Weight loss is one of the best-documented interventions for reducing the severity of obstructive sleep apnea
Hypertension — Untreated sleep apnea is one of the more common, reversible causes of hypertension resistant to standard treatment
Safety
Side effects & contraindications
Possible side effects
Untreated moderate-to-severe sleep apnea is associated with elevated risk of hypertension, atrial fibrillation, stroke, and heart failure
Chronic sleep fragmentation and intermittent hypoxia worsen daytime sleepiness, impair mood, and raise the risk of insulin resistance
CPAP therapy is generally well tolerated, but in some patients causes dry nose and throat mucosa, a feeling of claustrophobia, or skin irritation where the mask makes contact
Contraindications
Adaptive servo-ventilation is contraindicated in heart failure patients with reduced ejection fraction and predominant central sleep apnea — the SERVE-HF trial showed increased mortality in this group
Unsupervised, unconsulted changes to CPAP settings in patients with unstable heart failure or mixed sleep apnea require oversight from a sleep medicine specialist
Interactions
Alcohol and sedative medications (including benzodiazepines) relax throat muscles and worsen both the frequency and duration of obstructive episodes
Opioids directly suppress the brainstem respiratory center and can trigger or worsen central sleep apnea
Weight gain worsens OSA severity, and weight loss is one of the best-documented interventions for reducing the apnea index
Heart failure promotes Cheyne-Stokes breathing and central sleep apnea independent of body weight
High altitude can trigger periodic breathing resembling central sleep apnea even in people with no prior breathing disorder
Smoking and chronic inflammation of the upper airway mucosa worsen throat swelling and obstruction
Is it worth taking?
Who it's for
- People who are overweight or obese, especially with a large neck circumference and loud, irregular snoring noticed by a partner
- Men over 40 and postmenopausal women, in whom OSA risk rises significantly
- Patients with heart failure, atrial fibrillation, treatment-resistant hypertension, or a history of stroke — groups at elevated risk for both OSA and CSA
- People reporting excessive daytime sleepiness, morning headaches, a choking sensation at night, or unexplained fatigue and insomnia despite seemingly adequate hours of sleep
Not for
- Adaptive servo-ventilation is contraindicated in heart failure patients with reduced ejection fraction and predominant central sleep apnea — the SERVE-HF trial showed increased mortality in this group
- Unsupervised, unconsulted changes to CPAP settings in patients with unstable heart failure or mixed sleep apnea require oversight from a sleep medicine specialist
Evidence
Worth knowing
An estimated nearly a billion adults aged 30-69 worldwide have obstructive sleep apnea of some severity.
Central sleep apnea is far rarer than obstructive sleep apnea and, in most cases, secondary to another condition, most often heart failure.
The apnea-hypopnea index (AHI) classifies severity as mild (5-15/hr), moderate (15-30/hr), and severe (above 30/hr), but treatment decisions always factor in clinical symptoms too, not the number alone.
In adults with an uncomplicated, high clinical probability of OSA, home sleep apnea testing (HSAT) is an accepted alternative to full in-lab polysomnography.
Studies
An estimated nearly a billion adults aged 30-69 worldwide have obstructive sleep apnea, a substantial share of whom have a moderate-to-severe form.
Benjafield A.V. et al., The Lancet Respiratory Medicine, 2019
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis
Strong evidenceBenjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A · The Lancet Respiratory Medicine · 2019
A literature-based analysis combining epidemiological data from more than a dozen countries with population modeling, estimating the global burden of obstructive sleep apnea at nearly a billion adults aged 30-69.
View studyClinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline
Strong evidenceKapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG · Journal of Clinical Sleep Medicine · 2017
American Academy of Sleep Medicine guidelines on diagnosing obstructive sleep apnea in adults, including the conditions under which home sleep apnea testing (HSAT) is an accepted alternative to full polysomnography.
View studySources & bibliography
- Benjafield et al. 2019 — The Lancet Respiratory Medicine
- Kapur et al. 2017 — Journal of Clinical Sleep Medicine (AASM)
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
Redakcja VitMode — Hormony i endokrynologiaEditorial team
VitMode Editorial — Hormones and Endocrinology is the VitMode editorial team responsible for: hormones, testosterone therapy, the thyroid and metabolism. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.
328 publications on this site
Editorial review
Redakcja VitMode — Sen i neurobiologiaEditorial team
VitMode Editorial — Sleep and Neurobiology is the VitMode editorial team responsible for: sleep, circadian rhythm, cognition and recovery. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.
118 publications on this site
Related entries
Sleep
Sleep isn't a passive shutdown of the body — it's an active, highly organized biological process. Its shortfall (and, counterintuitively, its excess too) is linked to a measurably higher risk of death from any cause.
Obesity
A chronic disease linked to excess body fat — and its relationship with mortality, mapped in the largest available meta-analysis covering over 10 million participants, has the shape of a curve, not a straight line.
Hypertension
The 'silent killer' — it runs symptom-free for years, yet it's one of the strongest, and largely modifiable, risk factors for stroke and heart attack in the world.
Insomnia
Chronic difficulty falling or staying asleep isn't just a matter of 'sleep hygiene' — the best-studied intervention, recommended as first-line treatment, is cognitive behavioral therapy for insomnia (CBT-I), not sleeping pills.
Cortisol
The main stress hormone — essential for short-term survival, but problematic when chronically elevated.
Excessive Daytime Sleepiness
Excessive daytime sleepiness (EDS) isn't a disease in itself — it's a symptom. Behind a persistent difficulty staying alert during the day can lie more than a dozen different causes, from ordinary sleep deprivation to sleep apnea, medications, or — far more rarely — narcolepsy.
Polysomnography (Sleep Study)
Polysomnography (PSG) is a comprehensive test that simultaneously records brain activity, eye movements, muscle tone, airflow, respiratory effort, blood oxygen saturation, and heart rhythm throughout a full night's sleep — the gold standard for diagnosing breathing disorders and assessing sleep architecture.
Sleep and Growth Hormone / Cortisol Secretion
Sleep architecture — specifically the presence of deep slow-wave sleep — directly drives the largest daily pulse of growth hormone, while sleep acts as an anchor synchronizing the daily cortisol rhythm. Disrupted sleep dysregulates both systems regardless of how many hours we actually spend in bed.
Related articles
PoradnikiSleep Apnea and Weight Loss — Is Losing Weight Enough to Cure It?
Obesity is one of the strongest risk factors for obstructive sleep apnea, and weight loss — even the drastic kind achieved through bariatric surgery — can markedly improve its severity. But a meta-analysis of bariatric surgery studies reveals something rarely stated outright: despite the huge improvement, the average patient's sleep apnea usually doesn't disappear completely. It remains, just in a milder form — which has concrete, practical implications for the decision to continue treatment.
August 25, 2026
PoradnikiSleep Apnea: Symptoms, Causes, and How Diagnosis Works
Loud snoring interrupted by silence, morning headaches, and daytime sleepiness despite what looks like a full night's sleep — obstructive sleep apnea is often dismissed for years, because most of its symptoms are noticed by a partner, not the patient. Yet untreated apnea isn't just about worse quality of life: it carries a measurably higher cardiovascular risk, confirmed in meta-analyses covering tens of thousands of people. Here's how to recognize the symptoms, what a sleep study actually involves, and what real treatment options exist beyond CPAP alone.
September 13, 2026
PoradnikiMouth Taping for Sleep — Is It Safe?
Taping your mouth shut before bed is one of the most popular biohacking trends of the past few years — promising less snoring, better sleep, and no more dry mouth. The problem is that a 2025 systematic review found no convincing evidence for these benefits in the average person, while describing a real, well-documented risk — especially for people with undiagnosed or diagnosed sleep apnea, for whom taping the mouth can remove a built-in safety mechanism: the ability to breathe through the mouth during an apnea event.
October 17, 2026
PoradnikiCPAP Alternatives for Treating Sleep Apnea
CPAP remains the gold standard for treating obstructive sleep apnea — but in clinical reality, a substantial share of patients can't tolerate it long-term. For people with a genuine, documented CPAP intolerance, three real, evidence-backed alternatives exist: oral appliances, positional therapy, and the implantable Inspire hypoglossal nerve stimulator — each with specific qualification criteria and limitations, not a universal substitute.
October 17, 2026
PoradnikiOxygen Saturation (SpO2): Normal Values, Pulse Oximeters and Smartwatches — How Accurate Is the Reading?
Oxygen saturation (SpO2) shows what share of the haemoglobin in the blood is loaded with oxygen. In one study a medical pulse oximeter was off by about 1 percentage point on average, but in a few percent of people the difference reached 4 points or more. We explain what disturbs the reading (cold hands, dark nail polish, movement, skin tone), how accurate watches and bands are at low saturation, which values are considered normal and when a low reading needs a doctor.
November 3, 2026
PoradnikiSleepy After Eating: Why You Feel Tired After Lunch
The heavy-eyelid afternoon after lunch is one of the most common adult experiences, yet the science explains it less obviously than popular wisdom about 'sugar' and 'carbs' suggests. Studies of meals of different composition and size show that the afternoon dip in alertness is largely a circadian phenomenon, and lunch mostly deepens it, especially after a short night. We explain what is actually known, how much blame belongs to glucose swings, when sleepiness after a meal can signal sleep apnoea or disturbed carbohydrate metabolism, and which simple changes make sense.
November 3, 2026
PoradnikiNocturnal Panic Attacks: Waking Up with Fear and a Racing Heart
Waking suddenly in the middle of the night with a racing heart, breathlessness, a sense of mortal danger and no memory of a bad dream can be a nocturnal panic attack. Between 44 and 71% of people with panic disorder report such episodes, and they occur in sleep without dreams (NREM). We explain how to tell them from nightmares, sleep apnoea, arrhythmia or low blood sugar, what research says about cognitive behavioural therapy and when it is worth checking the heart, thyroid and sleep.
October 29, 2026
PoradnikiCluster Headache: Symptoms, Attack Treatment and Prevention
Cluster headache is a rare, extremely severe, one-sided pain around the eye, lasting 15 to 180 minutes and returning in series, often at the same time of day. An attack is best aborted by 100% oxygen at a flow of at least 12 L/min and by sumatriptan 6 mg subcutaneously — both have strong recommendations in the European guideline. Prevention is built on verapamil at a dose of at least 240 mg a day, and the newer anti-CGRP antibodies give less here than expected. We describe the symptoms, the triggers (especially alcohol during a cluster period), diagnostic mix-ups and why a first headache of this kind always needs a neurologist's assessment.
October 26, 2026